What is the utility of a multigated acquisition (MUGA) scan?

MUGA Scan Utility

A MUGA scan is primarily useful as an alternative imaging modality for measuring left ventricular ejection fraction (LVEF) when echocardiography is not available or technically feasible, though it has significant limitations including high misclassification rates and lack of structural cardiac information 1, 2.

Primary Clinical Applications

Cardio-Oncology Monitoring

The MUGA scan's main utility is in serial assessment of LVEF in patients receiving cardiotoxic chemotherapy (particularly anthracyclines and HER2-targeted therapies) 3. However, this represents a second-line role:

• Echocardiography is the preferred imaging modality for monitoring asymptomatic oncology patients due to superior portability, availability, safety, and comprehensive cardiac assessment 2
• MUGA should only be considered when echocardiography is not available or technically inadequate (poor image quality from body habitus, chronic lung disease, or prior mediastinal surgery) 2
• When echocardiography is unavailable, cardiac MRI is preferred over MUGA 2

Heart Failure Assessment

MUGA can determine accurate LVEF in patients with intractable heart failure when other modalities are limited 3.

Critical Limitations

Accuracy Concerns

MUGA has substantial accuracy problems that directly impact patient care:

• Misclassifies 20% of patients at LVEF threshold of 55% and 35% of patients at threshold of 50% when compared to cardiac MRI 1, 4
• Wide limits of agreement (-19.4 to +16.5%) compared to CMR reference standard 4
• These misclassification rates are clinically significant and can lead to inappropriate treatment decisions

Lack of Comprehensive Information

Unlike echocardiography or cardiac MRI, MUGA provides:

• No information about cardiac structure or morphology 1
• No assessment of valvular disease
• No evaluation of diastolic function
• No tissue characterization
• No assessment of right ventricular function (unless combined with first-pass imaging) 3

Interchangeability Issues

MUGA and other imaging modalities should NOT be used interchangeably for serial monitoring 5:

• MUGA vs. CMR: Poor agreement, cannot substitute
• MUGA vs. 2D echocardiography: Variable correlation
• If baseline imaging is performed with MUGA, subsequent studies may use 3D echocardiography or 2D harmonic echocardiography with contrast as appropriate alternatives 5
• Consistency in imaging technology and analysis software is essential to limit technical variability 2

Cost-Effectiveness Considerations

The clinical utility of routine baseline MUGA screening is questionable:

• Only 2.5% of patients have abnormal baseline LVEF 6
• Only 1.6% have chemotherapy decisions changed based on results 6
• Cost-effectiveness improves with patient age >40 years and cumulative doxorubicin doses ≥350 mg/m² 7

Common Pitfalls

1. Using MUGA and echocardiography interchangeably for serial monitoring - this introduces measurement variability that can be misinterpreted as true changes in cardiac function
2. Relying solely on LVEF from MUGA without considering that structural abnormalities, valvular disease, or diastolic dysfunction may be missed
3. Assuming MUGA is more accurate than echocardiography - recent evidence shows significant misclassification rates 1, 4